These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33932126)

  • 1. End-to-end application of model-informed drug development for ertugliflozin, a novel sodium-glucose cotransporter 2 inhibitor.
    Fediuk DJ; Nucci G; Dawra VK; Callegari E; Zhou S; Musante CJ; Liang Y; Sweeney K; Sahasrabudhe V
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):529-542. PubMed ID: 33932126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.
    Marshall JC; Liang Y; Sahasrabudhe V; Tensfeldt T; Fediuk DJ; Zhou S; Krishna R; Dawra VK; Wood LS; Sweeney K
    J Clin Pharmacol; 2021 Sep; 61(9):1220-1231. PubMed ID: 33813736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
    Callegari E; Lin J; Tse S; Goosen TC; Sahasrabudhe V
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):127-136. PubMed ID: 33314761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
    Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
    Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
    Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
    Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
    Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.
    Li Y; Mu Y; Shi H; Liang Y; Liu Z; Matschke K; Hickman A; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):97-106. PubMed ID: 30934166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
    Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects.
    Li Y; Nucci G; Yamamoto Y; Fediuk DJ; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):765-776. PubMed ID: 33434408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.
    Raje S; Callegari E; Sahasrabudhe V; Vaz A; Shi H; Fluhler E; Woolf EJ; Schildknegt K; Matschke K; Alvey C; Zhou S; Papadopoulos D; Fountaine R; Saur D; Terra SG; Stevens L; Gaunt D; Cutler DL
    Clin Transl Sci; 2018 Jul; 11(4):405-411. PubMed ID: 29575530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
    Dawra VK; Pelletier K; Matschke K; Shi H; Hickman A; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2021 May; 10(5):510-520. PubMed ID: 33135865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
    Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations.
    Fediuk DJ; Sahasrabudhe V; Dawra VK; Zhou S; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1297-1306. PubMed ID: 34213819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
    Frias JP
    Expert Rev Endocrinol Metab; 2019 Mar; 14(2):75-83. PubMed ID: 30724637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
    Powell J; Garland SG
    Ann Pharmacother; 2019 May; 53(5):478-485. PubMed ID: 30522346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
    Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
    Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
    Liu J; Pong A; Gallo S; Darekar A; Terra SG
    Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ertugliflozin: First Global Approval.
    Markham A
    Drugs; 2018 Mar; 78(4):513-519. PubMed ID: 29476348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.